NVAX240705C14000
- 0.01
- -0.01-50.00%
Novavax Newsroom
After falling to an 11-year low and consolidating for several months, should I buy or sell pfizer (PFE.US) now?
In April of this year, Pfizer (PFE.US) stock price fell to its lowest point since January 2013. As of the closing price on July 1, the stock has risen by about 11% since then; After falling to an 11-year low, Pfizer has been consolidating for several months. So, should you buy or sell Pfizer stocks now? From a fundamental perspective, Pfizer is still trying to overcome the drag from the cooling of its COVID-19 products and actively promote the development of non-COVID-19 drug business. Recently, the company announced positive trial results of two potential anticancer drugs, but also closed a gene therapy project, and the company's stock price continues to trade sideways. In a study, patients who received Pfizer Elrex
(NVAX) - Analyzing Novavax's Short Interest
Novavax's (NYSE:NVAX) short percent of float has risen 3.9% since its last report. The company recently reported that it has 39.71 million shares sold short, which is 34.36% of all regular shares that
COVID Infections Could Be Seeing a Summer Surge Based on CDC Data
Novavax Seeks Health Canada Approval for Updated Covid-19 Vaccine
Novavax (NVAX) said Tuesday that it has submitted an application with Health Canada for authorization of its 2024-2025 Formula Covid-19 vaccine for individuals 12 years and older. The updated vaccine
Express News | Novavax Inc - Intends to Have Its Vaccine Available in Canada for Immediate Release Post-Authorization
Express News | Novavax Submits Application to Health Canada for Updated Protein-Based 2024-2025 Formula Covid-19 Vaccine
Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax's COVID-19 vaccine would be the only protein-based option available in Canada, if authorizedNovavax's filing is aligned with NACI, U.S. FDA, EMA and WHO recommendations on vaccine compositionG
Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
Where Will Novavax Be in 1 Year?
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
Express News | U.S. Cdc: Updated 2024-2025 Flu Vaccines Will All Be Trivalent and Will Protect Against an H1N1, H3N2 and a B/Victoria Lineage Virus
Express News | U.S. Cdc: Updated Covid-19 Vaccines Will Be Available From Moderna, Novavax, and Pfizer Later This Year
Express News | Novavax- Updated Version of Novavax Covid-19 Vaccine Currently Under Review by U.S. FDA for Eua to Prevent Covid-19 in Individuals Aged 12 and Older
Express News | Novavax - Intends to Provide Doses of 2024-2025 Covid-19 Vaccine at Start of Vaccination Season and Upon Eua by U.S. Food and Drug Administration
Express News | Novavax Inc - U.S. Acip Recommends Use of Authorized and Approved 2024-2025 Covid-19 Vaccines
Express News | U.S. Cdc Advisers Recommend Updated Covid-19 Vaccines for Persons Aged Six Months and Above
Novavax Insiders Sold US$593k Of Shares Suggesting Hesitancy
Novavax, Inc. (NASDAQ:NVAX) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When evaluating insider transactions, knowing whether insiders are
U.S. ACIP Recommends Use of Authorized and Approved 2024-2025 COVID-19 Vaccines
Today the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of a universal recommendation for the use of 2024-2025
Decoding Novavax's Options Activity: What's the Big Picture?
Whales with a lot of money to spend have taken a noticeably bullish stance on Novavax.Looking at options history for Novavax (NASDAQ:NVAX) we detected 10 trades.If we consider the specifics of each tr
Novavax(NVAX.US) Director Sells US$105.68K in Common Stock
$Novavax(NVAX.US)$ Director YOUNG JAMES F sold 7,500 shares of common stock on Jun 21, 2024 at an average price of $14.09 for a total value of $105.68K.Source: Announcement What is statement of change